PT-141 (Bremelanotide) vs AOD-9604: Real-World Evidence Comparison

What Are These Two Peptides and Why Compare Them?

PT-141 and AOD-9604 are both peptide compounds that have attracted significant telehealth and compounding pharmacy interest, but they address entirely different clinical problems. PT-141 carries FDA approval for a defined psychiatric-sexual diagnosis. AOD-9604 has Phase 2 human data but remains outside any FDA drug-approval pathway.

Patients sometimes encounter both peptides on the same compounding pharmacy menu or wellness platform, which creates the false impression they are interchangeable or in the same therapeutic class. They are not. The comparison below is structured to answer the practical clinical question: given a specific patient presentation, which compound has evidence supporting its use, and what does that evidence actually say?

PT-141 (Bremelanotide): Mechanism and Pharmacology

Melanocortin Receptor Activation

PT-141 is a cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH). It binds melanocortin receptors MC1R, MC3R, and MC4R with high affinity [1]. MC4R activation in the paraventricular nucleus of the hypothalamus is the pathway most strongly linked to pro-sexual behavior in animal and human models [2].

Unlike phosphodiesterase-5 inhibitors, PT-141 does not act on vascular smooth muscle. Its mechanism is entirely central, which is why the FDA approved it specifically for the desire-phase diagnosis of HSDD rather than arousal-phase or orgasm-phase disorders [3].

Approved Formulation and Dosing

The FDA-approved product (Vyleesi, AMAG Pharmaceuticals) is a 1.75 mg/0.3 mL subcutaneous auto-injector. Patients administer a single dose 45 minutes before anticipated sexual activity, with a maximum of one dose per 24 hours and eight doses per month [3].

Compounding pharmacies also prepare PT-141 as an intranasal formulation at doses ranging from 0.5 mg to 2 mg per spray. The intranasal route has a faster time to peak plasma concentration (roughly 30 minutes) but lower and more variable bioavailability than subcutaneous injection [4].

The RECONNECT Key Trials

The FDA approval rested on two identical Phase 3 randomized controlled trials known collectively as RECONNECT (N=1,247 premenopausal women with HSDD). Published in Obstetrics and Gynecology in 2019, these trials demonstrated that bremelanotide produced a statistically significant increase of 0.5 additional satisfying sexual events (SSEs) per month compared to placebo (P<0.001) and a 1.2-point reduction on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) Item 13 score (P<0.001) [1].

Those effect sizes are modest by absolute standards. The investigators noted that the proportion of responders who reported meaningful benefit was 25% for bremelanotide versus 17% for placebo. Nausea occurred in 40% of treated participants, which drove a discontinuation rate roughly three times higher than placebo [1].

AOD-9604: Mechanism and Pharmacology

HGH Fragment 176-191 and Lipolysis

AOD-9604 is a 16-amino-acid synthetic peptide corresponding to residues 176 through 191 of the C-terminal end of human growth hormone. The fragment retains the lipolytic properties of intact GH but loses the anabolic and insulin-sensitizing domains responsible for IGF-1 stimulation [5].

In preclinical work by Ng et al. (1997), AOD-9604 reduced body fat in obese mice by 50% over six weeks at doses of 500 mcg/kg without altering blood glucose or IGF-1 levels [6]. That metabolic selectivity was the basis for advancing the compound to human trials.

Human Phase 2 Data

Heffernan et al. (Endocrinology, 2001) conducted the most-cited human dose-ranging study of AOD-9604 (N=300 adults with BMI 27-40 kg/m²) [7]. At an oral dose of 1 mg/day for 12 weeks, participants lost a mean 2.6 kg of body fat versus 0.8 kg in placebo (P<0.05). Higher oral doses (5 mg, 10 mg, 30 mg) did not outperform the 1 mg group, suggesting a non-linear dose-response [7].

A subsequent Phase 2b trial by Metabolic Pharmaceuticals (the developer) evaluated doses up to 54 mg/day without demonstrating statistically significant weight loss superiority over placebo, and the Phase 3 development program was discontinued [8]. The compound never reached NDA submission.

Regulatory Status

In 2014, the FDA issued a determination that AOD-9604 is not a bulk drug substance that can be compounded under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act, specifically because it lacks an approved NDA and was not marketed prior to 1962 [9]. Compounding pharmacies that prepare AOD-9604 for subcutaneous injection operate in a regulatory gray zone. Prescribers should review the current FDA 503A/503B bulk substance lists before prescribing [9].

Head-to-Head Efficacy: What the Evidence Actually Shows

Comparing Trial Quality

PT-141 and AOD-9604 are not competitive alternatives. They have been studied for different outcomes. A direct efficacy comparison requires separate endpoints.

For HSDD, PT-141 has two well-powered Phase 3 RCTs and FDA approval. No randomized trial has ever tested AOD-9604 for sexual function. For fat loss, AOD-9604 has Phase 2 human RCT data showing 2.6 kg fat loss at 12 weeks, but its Phase 3 program failed [7]. PT-141 was never studied for adiposity.

The table below summarizes the evidence gap.

| Domain | PT-141 | AOD-9604 | |---|---|---| | Highest evidence level | Phase 3 RCT x 2, FDA-approved | Phase 2 RCT, no approval | | Primary outcome studied | Satisfying sexual events (HSDD) | Body fat mass (obesity) | | Statistically significant Phase 3 result | Yes [1] | No (Phase 3 discontinued) [8] | | FDA approval | Yes (Vyleesi, June 2019) [3] | No [9] | | Compounding status | Allowed (503A/B with active ingredient) | Restricted under current FDA guidance [9] |

Effect Sizes in Context

PT-141's RECONNECT result of 0.5 additional SSEs per month is statistically significant but sits at the lower boundary of what many sexual medicine clinicians consider clinically meaningful [1]. The FDA's own advisory committee deliberated at length about whether the effect size justified approval, ultimately deciding that patient-reported distress reduction was a sufficient secondary anchor [3].

AOD-9604's 2.6 kg fat loss at 12 weeks compares unfavorably to semaglutide 2.4 mg (Wegovy), which produced 14.9% mean body weight loss at 68 weeks in STEP-1 (N=1,961) [10]. For patients whose primary goal is fat loss, GLP-1 receptor agonists have a substantially larger and better-replicated evidence base.

Safety Profiles: Side Effects and Monitoring

PT-141 Safety Data

The RECONNECT safety population (N=1,913 total exposure) documented nausea in 40.0% of participants, flushing in 20.4%, and a transient blood pressure increase (mean 6 mmHg systolic, lasting up to 12 hours) in a clinically relevant subset [1]. The FDA label carries a contraindication for patients with high cardiovascular risk and advises against use with antihypertensives that have sexual side effects [3].

Hyperpigmentation has been reported with repeated use due to MC1R activation. The FDA label notes this as a known adverse effect of the melanocortin mechanism [3]. Patients with personal or family histories of melanoma should discuss risk-benefit with their provider before initiating PT-141 [2].

AOD-9604 Safety Data

AOD-9604's safety profile in humans is limited to Phase 2 exposure. Heffernan et al. Reported no clinically significant changes in fasting glucose, insulin, IGF-1, lipids, or thyroid function at any dose tested over 12 weeks [7]. Injection-site reactions were the most commonly reported adverse event in subcutaneous-dosing cohorts.

Long-term safety data in humans simply do not exist. The absence of Phase 3 trial data means there is no large-scale safety database equivalent to what PT-141 accumulated through its FDA approval process. Patients and prescribers should treat that data gap as a material unknown, not as evidence of safety.

A Clinical Decision Framework: Which Patients Belong on Which Compound

Consider PT-141 when:

• The primary complaint is low sexual desire with documented distress in a premenopausal woman.
• The patient has failed or declined flibanserin (Addyi).
• Cardiovascular risk is low to moderate and blood pressure is controlled.
• The prescriber can supply the FDA-approved Vyleesi auto-injector or a compounded formulation with a documented quality COA.

Consider AOD-9604 only when:

• The clinical goal is research-context fat loss and the patient understands the compound is not FDA-approved.
• The patient has been counseled on the negative Phase 3 result and the regulatory restrictions on compounding.
• The prescriber has confirmed that their compounding pharmacy holds current 503A/503B compliance documentation.
• GLP-1 receptor agonists are contraindicated or declined.

Do not combine the two compounds for "synergistic" effect. No published trial has ever studied the combination, and the mechanistic pathways (melanocortin CNS signaling vs. Peripheral lipolysis) do not suggest additive benefit on any single clinical endpoint [2][7].

Dosing Protocols: Practical Prescribing Details

PT-141 Dosing

FDA-approved dosing: 1.75 mg SC as needed, no more than once per 24 hours, no more than eight times per month [3]. Onset is 45 minutes; duration of effect is approximately 12 hours.

Compounded intranasal PT-141: typically 0.5 to 1 mg per dose, 30 to 45 minutes before activity. Lower doses reduce nausea incidence but may also reduce efficacy. No published dose-optimization RCT exists for the intranasal route; prescribers rely on case-series data and compounding pharmacy pharmacokinetic modeling [4].

For patients who experience significant nausea, pre-treatment with ondansetron 4 mg orally 30 minutes prior to PT-141 administration is a common clinical strategy, though no RCT has validated this approach [11].

AOD-9604 Dosing

Oral dosing in the Heffernan Phase 2 trial: 1 mg once daily for 12 weeks produced the best fat-loss result [7]. Higher oral doses did not improve outcomes. The oral route was chosen specifically because peptide degradation in the GI tract limits systemic absorption, and AOD-9604's small size (1.82 kDa) makes partial oral bioavailability feasible.

Subcutaneous dosing is common in telehealth settings, typically 250 to 300 mcg once daily in the morning, fasted. This dosing regimen is extrapolated from preclinical data and is not validated by any published human RCT [6]. Prescribers using SC AOD-9604 are working entirely outside the published evidence base.

Switching From PT-141 to AOD-9604 (or Vice Versa)

When Patients Ask About Switching

Patients occasionally ask about switching between these two compounds after reading wellness forums that group all peptides into a single category. The clinical answer is straightforward: switching between PT-141 and AOD-9604 is not a pharmacological concept because the two drugs treat different conditions via unrelated mechanisms.

A patient on PT-141 for HSDD who also wants fat loss should have a separate clinical conversation about weight management options. Discontinuing PT-141 to start AOD-9604 would leave the HSDD untreated. Similarly, a patient using AOD-9604 for research-context fat loss who develops HSDD symptoms should be evaluated for PT-141 or flibanserin independently.

Washout Considerations

PT-141 has a half-life of approximately 2.7 hours and is cleared within 24 hours of a single dose, so no washout period is needed before starting an unrelated compound [3]. AOD-9604 has a short half-life estimated at under 30 minutes for the SC route [5]. No pharmacokinetic interaction between these two peptides has been reported or studied.

Insurance, Cost, and Access

PT-141 (Vyleesi branded product) is not typically covered by commercial insurance and carries a list price near $800 per auto-injector. Compounded bremelanotide from a 503A pharmacy is typically $60 to $150 per multi-dose vial, which substantially reduces the cost barrier [3].

AOD-9604 is not covered by any insurance because it lacks an approved indication. Compounded AOD-9604 vials typically cost $80 to $200 per month depending on dose and supplier. Patients should verify that their compounding pharmacy is FDA-registered and can provide a current certificate of analysis before use [9].

What Clinicians and Guidelines Say

The International Society for the Study of Women's Sexual Health (ISSWSH) 2021 process-of-care consensus statement names bremelanotide as a second-line option for HSDD after flibanserin, noting that "bremelanotide's on-demand dosing schedule provides a clinical advantage for patients who do not prefer daily pharmacotherapy" [12].

No major endocrinology or obesity-medicine guideline currently recommends AOD-9604. The Endocrine Society's 2015 obesity pharmacotherapy guideline does not mention it [13]. The American Association of Clinical Endocrinology (AACE) 2016 obesity algorithm does not reference HGH fragment peptides as approved or evidence-based options [14].

FAQ